Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans reduced its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,812 shares of the company's stock after selling 5,820 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.10% of Prestige Consumer Healthcare worth $3,968,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Cibc World Markets Corp acquired a new position in Prestige Consumer Healthcare in the fourth quarter valued at approximately $362,000. Corient Private Wealth LLC lifted its position in shares of Prestige Consumer Healthcare by 331.6% during the 4th quarter. Corient Private Wealth LLC now owns 15,163 shares of the company's stock worth $1,184,000 after buying an additional 11,650 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at $291,000. Natixis Advisors LLC boosted its stake in Prestige Consumer Healthcare by 1,335.1% in the fourth quarter. Natixis Advisors LLC now owns 209,246 shares of the company's stock valued at $16,340,000 after acquiring an additional 194,665 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Prestige Consumer Healthcare by 0.5% in the 4th quarter. Swiss National Bank now owns 97,500 shares of the company's stock valued at $7,614,000 after purchasing an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares of the company's stock, valued at $1,544,130. The trade was a 8.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Trading Down 1.2 %

Shares of PBH stock traded down $1.03 during mid-day trading on Friday, hitting $85.01. 314,373 shares of the company's stock were exchanged, compared to its average volume of 271,302. The stock has a 50-day simple moving average of $83.30 and a two-hundred day simple moving average of $78.97. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. The stock has a market cap of $4.21 billion, a price-to-earnings ratio of 19.91, a PEG ratio of 2.69 and a beta of 0.46. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analyst Ratings Changes

PBH has been the subject of several research reports. Canaccord Genuity Group upped their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Royal Bank of Canada lifted their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a report on Friday, March 21st. DA Davidson upped their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Finally, Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.